Switch theme
Sign up to access all valuation multiples
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
2003
42
Last FY Revenue n/a
LTM EBITDA -$35.2M
$192M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Candel Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$35.2M.
In the most recent fiscal year, Candel Therapeutics achieved revenue of n/a and an EBITDA of -$52.1M.
Candel Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Candel Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$35.2M | XXX | -$52.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$36.3M | XXX | -$33.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$50.4M | XXX | -$55.2M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Candel Therapeutics's stock price is $5.
Candel Therapeutics has current market cap of $273M, and EV of $192M.
See Candel Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $192M | $273M | XXX | XXX | XXX | XXX | $-1.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Candel Therapeutics has market cap of $273M and EV of $192M.
Candel Therapeutics's trades at n/a EV/Revenue multiple, and -3.7x EV/EBITDA.
Equity research analysts estimate Candel Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Candel Therapeutics has a P/E ratio of -5.4x.
See valuation multiples for Candel Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $273M | XXX | $273M | XXX | XXX | XXX |
| EV (current) | $192M | XXX | $192M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -5.4x | XXX | -3.7x | XXX | XXX | XXX |
| EV/EBIT | -5.3x | XXX | -5.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.4x | XXX | -4.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCandel Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.8M for the same period.
Candel Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Candel Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Candel Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Candel Therapeutics acquired XXX companies to date.
Last acquisition by Candel Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Candel Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Candel Therapeutics founded? | Candel Therapeutics was founded in 2003. |
| Where is Candel Therapeutics headquartered? | Candel Therapeutics is headquartered in United States of America. |
| How many employees does Candel Therapeutics have? | As of today, Candel Therapeutics has 42 employees. |
| Who is the CEO of Candel Therapeutics? | Candel Therapeutics's CEO is Dr. Paul Peter Tak, M.D.,PhD. |
| Is Candel Therapeutics publicy listed? | Yes, Candel Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Candel Therapeutics? | Candel Therapeutics trades under CADL ticker. |
| When did Candel Therapeutics go public? | Candel Therapeutics went public in 2021. |
| Who are competitors of Candel Therapeutics? | Similar companies to Candel Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Candel Therapeutics? | Candel Therapeutics's current market cap is $273M |
| Is Candel Therapeutics profitable? | Yes, Candel Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Candel Therapeutics? | Candel Therapeutics's last 12 months EBITDA is -$35.2M. |
| What is the current EV/EBITDA multiple of Candel Therapeutics? | Current EBITDA multiple of Candel Therapeutics is -5.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
